DCOY is trading 6.9% down at $5.50 after the SEC declared its S-1 registration effective, clearing the path for Decoy Therapeutics’ planned IPO and related securities offering.
- Investors appear focused on potential dilution and increased share supply, which is pressuring the stock in after-hours trading.
- The downward movement comes despite broader markets showing only modest declines during the same period.